Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.
Contact us to learn how Vital Transformation can help your organisation.
LATEST RESEARCH
LATEST COMMUNICATIONS
Our Communication Services
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two key voices driving the PRIME-ROSE initiative: Gro Live Fagereng, Project Manager of the EU-project PRIME-ROSE and Coordinator of Precision Cancer Medicine at Oslo University Hospital, and Henk van der Pol, Ph.D. Candidate at Leiden University Medical Center. They explain the DRUP (Drug Rediscovery Protocol) trial approach, which repurposes existing oncology drugs for new off-label uses, and discuss how this can widen treatment options for patients with rare or underserved tumor types. They also describe the complexities of consolidating small patient cohorts across multiple sites and countries, shedding light on how data models like OMOP help standardize clinical information.
Find all our communication projects on Better Science, Better Health
MORE RESEARCH
Unlocking the value of personalised healthcare in Europe—breast cancer stratification
June, 2012
Abstract
Through stratification, this simulation shows that there is great potential to improve the efficiency of treating breast cancer. By segmenting the female population at the age of 50 based on family history and genetic testing, our model shows a reduction in costs of breast cancer treatments by 37% with no loss of efficacy accomplished primarily through a 60% drop in incidence of metastatic stages of the disease
VITAL HEALTH PODCASTS
Our podcast series is also available via your favourite channels!
 |
 |
|---|---|
 |
 |
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…
VT on X
The Inflation Reduction Act's Impact upon Early-stage Venture Capital Investments
— Duane Schulthess (@DuaneSchulthess) January 8, 2025
-Aggregate small molecule investments declined by 70%
-Individual small molecule investments decline in size by -50% as exposure to Medicare increases (p < 0.0018).https://t.co/JMfjrToyxe
New study "The EU General Pharmaceutical Legislation & Clawbacks: Calculated impacts – both designed and unintended." https://t.co/issED0DnUn@amgen @AbbVie @IAmBiotech @DuaneSchulthess @BSBHbyVT @VitalTransform @abbvieuk
— VitalTransformation (@VitalTransform) April 18, 2024
Our clients include many of the world’s leading health care organisations.
